Company Contents
Quick Facts & Snapshot
Summary
The global Blood Preparation market is entering a consolidation-driven growth phase, underpinned by rising transfusion volumes, safety regulations, and automation. Top Blood Preparation market companies are strengthening portfolios in plasma derivatives, anticoagulants, and pathogen reduction systems. The market is projected to reach US$ 76.20 Billion by 2032, reflecting a 6.20% CAGR from 2025 to 2032.
Source: Secondary Information and ReportMines Research Team - 2026
Ranking Methodology
The rankings of Blood Preparation market companies are derived from a composite scoring model blending quantitative and qualitative indicators. Core criteria include 2025 Blood Preparation revenue, three-year growth trajectory, and share of global plasma fractionation or blood component processing volumes. We also assess project wins with major hospital networks, blood banks, and national transfusion services, as well as installed base of preparation equipment and reagents. Technology differentiation, such as pathogen reduction platforms and automated component separation, is weighted alongside portfolio breadth across whole blood, plasma, platelets, and anticoagulants. Geographic reach, service coverage, regulatory approvals, and ability to secure long-term supply and maintenance contracts contribute to the final score. Secondary factors include R&D intensity, digital integration, and partnership ecosystems. Each company receives normalized sub-scores, aggregated into a total ranking index that determines positions 1 through 10.
Top 10 Companies in Blood Preparation
Source: Secondary Information and ReportMines Research Team - 2026
Detailed Company Profiles
CSL Behring
CSL Behring is a global leader in plasma-derived therapies, supplying critical blood preparation products for immunology, hematology, and intensive care.
Grifols, S.A.
Grifols operates an integrated model combining plasma collection, fractionation, diagnostics, and transfusion solutions across developed and emerging markets.
Takeda Pharmaceutical (Plasma-Derived Therapies Unit)
Takeda’s Plasma-Derived Therapies Unit focuses on high-value specialty products addressing rare immunologic and hematologic disorders.
Octapharma AG
Octapharma is a major independent plasma fractionator with a diversified portfolio in immunology, hematology, and critical care segments worldwide.
Baxter International Inc.
Baxter provides hospital-centered blood preparation systems, including apheresis, IV solutions, and related consumables for transfusion services.
Terumo BCT
Terumo BCT specializes in apheresis and cell processing technologies that integrate blood preparation with advanced cell and gene therapy workflows.
Haemonetics Corporation
Haemonetics delivers plasma and blood collection systems combined with software that optimizes donor management and hospital blood utilization.
Fresenius Kabi
Fresenius Kabi offers integrated transfusion and apheresis solutions, combining devices, disposables, and injectable therapies for hospital blood services.
Maco Pharma
Maco Pharma focuses on consumables and kits that enhance safety and efficiency in blood collection, preparation, and transfusion.
Cerus Corporation
Cerus develops pathogen reduction systems that are integrated into blood preparation workflows to improve safety of platelets and plasma.
SWOT Leaders
CSL Behring
SWOT Snapshot
Extensive plasma collection footprint, diversified high-value portfolio, strong regulatory track record, and global distribution capabilities.
High fixed costs and dependence on donor availability make profitability sensitive to collection disruptions and regulatory changes.
Rising global demand for immunoglobulins, expansion into underpenetrated emerging markets, and innovation in subcutaneous delivery formats.
Tightening reimbursement pressures, potential new entrants with recombinant alternatives, and increasing scrutiny on plasma donor compensation models.
Grifols, S.A.
SWOT Snapshot
Vertically integrated model across plasma, diagnostics, and transfusion, supported by a large network of plasma centers and R&D sites.
Elevated leverage and portfolio complexity create financial and strategic execution risks in a volatile macro environment.
Efficiency gains from digital transformation, optimization of plasma network, and expansion of safety-focused Blood Preparation solutions.
Competitive pressure from other plasma majors, regulatory investigations, and possible restrictions on plasma collection practices in key countries.
Takeda Pharmaceutical (Plasma-Derived Therapies Unit)
SWOT Snapshot
Strong rare-disease brand equity, advanced R&D capabilities, and global compliance with stringent quality and safety standards.
Concentration in high-value niches reduces exposure to broader transfusion volumes and increases sensitivity to pricing negotiations.
Growing diagnosis and treatment of rare immunologic conditions, geographic expansion, and life-cycle management of flagship therapies.
Emerging biologic and gene therapies targeting similar indications, as well as tightening cost containment by payers worldwide.
Blood Preparation Market Regional Competitive Landscape
North America remains the largest and most profitable region for Blood Preparation market companies, driven by high transfusion rates, strong reimbursement frameworks, and extensive plasma collection infrastructure. CSL Behring, Grifols, Takeda, and Haemonetics leverage deep relationships with commercial plasma collectors and integrated health systems, while Cerus gains traction through pathogen reduction mandates and safety-focused procurement.
Europe exhibits a balanced mix of public and private blood services, emphasizing safety, donor protection, and cost effectiveness. Octapharma, Grifols, CSL Behring, and Fresenius Kabi hold significant share through long-term supply contracts with national health systems. Maco Pharma benefits from its extensive consumable portfolio, while Cerus capitalizes on progressive pathogen reduction policies in countries like France and Switzerland.
Asia Pacific is the fastest-growing region, underpinned by rising surgical volumes, growing awareness of blood safety, and expansion of hospital infrastructure. Takeda, Terumo BCT, CSL Behring, and Baxter focus on tiered offerings to meet varying affordability levels. Blood Preparation market companies increasingly localize manufacturing and partner with government programs to navigate regulatory diversity and pricing sensitivities.
Latin America and the Middle East & Africa offer high long-term potential but face budget constraints and uneven infrastructure. Fresenius Kabi, Grifols, Baxter, and Maco Pharma compete through cost-optimized solutions and donation system modernization projects. Development agencies and NGOs often co-fund safety upgrades, creating opportunities for Blood Preparation market companies with adaptable business models.
In China and broader emerging Asia, local manufacturers are strengthening capabilities in blood bags, collection sets, and basic plasma fractionation. Global Blood Preparation market companies such as CSL Behring, Grifols, and Takeda pursue joint ventures, technology transfer, and premium segments, while carefully managing pricing pressure and evolving regulatory requirements around plasma collection.
Blood Preparation Market Emerging Challengers & Disruptive Start-Ups
Emerging Challengers & Disruptive Start-Ups
Cloud-native decision-support platform using AI to optimize blood collection, preparation, and inventory, integrating seamlessly with devices from leading Blood Preparation market companies.
Develops compact, fully automated blood preparation workstations for mid-size hospitals, enabling on-site component separation with minimal operator intervention.
Focuses on cost-efficient plasma fractionation technologies tailored to emerging markets, offering modular plants suitable for regional blood centers.
Pursues novel low-energy pathogen reduction chemistry that can retrofit into existing preparation lines, targeting partnerships with established Blood Preparation market companies.
Mobile-first donor engagement and scheduling platform that integrates with blood banks, enhancing donor retention and data analytics for Blood Preparation market companies.
Blood Preparation Market Future Outlook & Key Success Factors (2026-2032)
From 2025 to 2031, cumulative investments in metro expansions and station safety upgrades are projected to surpass significant amounts. The total market will scale from US$ 2.27 Billionin 2025 to US$ 3.38 Billion by 2031, reflecting a 6.90% CAGR. Winning Blood Preparation market companies will share several attributes. First, they will embed native IoT sensors, enabling predictive maintenance contracts that can double recurring revenue within five years. Second, modular design philosophies—interchangeable panels, plug-and-play controllers—will shorten installation windows and appeal to cost-sensitive public operators.
Localization strategies will also define competitive edges. Suppliers that establish regional assembly plants to meet content rules in India, Brazil, or the U.S. are likely to capture bonus points in tenders. Finally, sustainability credentials will move from optional to mandatory. Recyclable composite panels, energy-efficient brushless motors, and life-cycle carbon disclosures will become bid differentiators. In short, the coming decade rewards Blood Preparationmarket companies that marry digital intelligence with manufacturing agility and regulatory foresight.
Frequently Asked Questions
Find answers to common questions about this company report.